Pfizer Q2 Earnings - Pfizer (NYSE:PFE)

Pfizer Inc PFE has reported a Q2 adjusted EPS of $2.04, up 92% Y/Y, well ahead of the consensus of $1.80.
The company achieved revenues of $27.7 billion, up 53%, beating the Wall Street estimate of $25.98 billion.
Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues.
COVID-19 treatment Paxlovid contributed $8.1 billion in global sales.
The company said it had recorded a $450 million inventory write-off in the second quarter related to its COVID-19 products that had exceeded or are expected to exceed their shelf lives.
FY22 Outlook: Pfizer reaffirms FY22 sales of $98 billion - $102 billion, versus the consensus of $102.92 billion.
The company has revised adjusted EPS guidance to $6.30 - $6.45 versus the earlier guidance of $6.25 - $6.45 and the consensus of $6.62.
Pfizer reiterates COVID-19 vaccine sales of $32 billion and around $22 billion in revenue for Paxlovid.
Price Action: PFE shares are up 1.06% at $52.50 during the premarket session on the last check Thursday.
Photo by x3 from Pixabay

Momentum35.22

Growth32.42

Quality69.49

Value31.23

Short

Medium

Long

Pfizer Shares Tick Higher On Posting Almost Double Q2 Profits, Reaffirms FY22 Sales Forecast For COVID-19 Products